Objects
Farrell, Michael, Shahbazi, Jeyran, Byrne, Marianne, Grebely, Jason, Lintzeris, Nicholas, Chambers, Mark, Larance, Briony, Ali, Robert, Nielsen, Suzanne, Dunlop, Adrian, Dore, Gregory J., McDonough, Michael, Montebello, Mark, Nicholas, Thomas, Weiss, Rob, Rodgers, Craig, Cook, Jon, Degenhardt, Louisa. Elsevier; 2022. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.
Montebello, Mark, Jefferies, Meryem, Lintzeris, Nicholas, Agonist Replacement For Cannabis Dependence Study Group (ARC-D),, Mills, Llewellyn, Bruno, Raimondo, Copeland, Jan, McGregor, Iain, Rivas, Consuelo, Jackson, Melissa A., Silsbury, Catherine, Dunlop, Adrian. Elsevier; 2022. Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial.
Lintzeris, Nicholas, Bhardwaj, Anjali, Chan, Therese, Kirby, Adrienne, Hall, Michelle, Jefferies, Meryem, Luksza, Jennifer, Shanahan, Marian, Kevin, Richard, Allsop, David, Mills, Llewellyn, Dunlop, Adrian, Copeland, Jan, McGregor, Iain, Bruno, Raimondo, Gugusheff, Jessica, Phung, Nghi, Montebello, Mark. American Medical Association; 2019. Nabiximols for the treatment of cannabis dependence: a randomized clinical trial.
Mills, Llewellyn, Lintzeris, Nicholas, Bruno, Raimondo, Montebello, Mark, Dunlop, Adrian, Deacon, Rachel M., Copeland, Jan, Jefferies, Meryem, Rivas, Consuelo, Mammen, Kristie. Wiley-Blackwell; 2020. Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence.
Black, Emma, Bruno, Raimondo, Childs, Steven, Reid, David, Holmes, Jennifer, Lintzeris, Nicholas, Mammen, Kristie, Mills, Llewellyn, Siefried, Krista J., Deacon, Rachel M., Shakeshaft, Anthony, Dunlop, Adrian J., Ezard, Nadine, Montebello, Mark. John Wiley & Sons; 2023. Substance use, socio-demographic characteristics, and self-rated health of people seeking alcohol and other drug treatment in New South Wales: baseline findings from a cohort study.
Jackson, Melissa A., Brown, Amanda L., Phung, Nghi, Allsop, Dave, Dunlop, Adrian J., Johnston, Jennifer, Clancy, Richard, McGregor, Iain, Bruno, Raimondo, Lintzeris, Nick, Montebello, Mark, Luksza, Jennifer, Bowman, Jenny. BioMed Central Ltd.; 2021. The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients.
Allsop, David J., Copeland, Jan, Booth, Jessica, McGregor, Iain S., Lintzeris, Nicholas, Dunlop, Adrian J., Montebello, Mark, Sadler, Craig, Rivas, Gonzalo R., Holland, Rohan M., Muhleisen, Peter, Norberg, Melissa M.. American Medical Association; 2014. Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial.
Mills, Llewellyn, Dunlop, Adrian, Montebello, Mark, Copeland, Jan, Bruno, Raimondo, Jefferies, Meryem, Mcgregor, Iain, Lintzeris, Nicholas. BioMed Central (BMC); 2022. Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder.
Lintzeris, Nicholas, Mills, Llewellyn, Kevin, Richard, Bhardwaj, Anjali, Dunlop, Adrian, Copeland, Jan, Mcgregor, Iain, Bruno, Raimondo, Kirby, Adrienne, Montebello, Mark, Hall, Michelle, Jefferies, Meryem. Elsevier; 2020. Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: results from a placebo-controlled randomised trial.
Black, Emma, Mammen, Kristie, Shakeshaft, Anthony, Siefried, Krista J., Farrell, Michael, Holmes, Jennifer, Lintzeris, Nicholas, Deacon, Rachel M., Ezard, Nadine, Mills, Llewellyn, Dunlop, Adrian J., Montebello, Mark, Reid, David, Childs, Steven, Bruno, Raimondo. Wiley-Blackwell; 2023. Health and Social Characteristics of Clients Reporting Amphetamine Type Substance Use at Entry to Public Alcohol and Other Drug Services in New South Wales, Australia, 2016–2019.
Farrell, Michael, Shahbazi, Jeyran, Nielsen, Suzanne, Dunlop, Adrian, Dore, Gregory J., McDonough, Michael, Montebello, Mark, Weiss, Rob, Rodgers, Craig, Cook, Jon, Degenhardt, Louisa, Chambers, Mark, Byrne, Marianne, Gholami, Jaleh, Zahra, Emma, Grebely, Jason, Lintzeris, Nicholas, Larance, Briony, Ali, Robert. Elsevier; 2024. 96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial.